Clinical trial
Phase I, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 in Subjects…
NCT00425347 · Facet Biotech, Industry · Completed
Key facts
| NCT number | NCT00425347 |
|---|---|
| Title | Phase I, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 in Subjects With Advanced Multiple Myeloma |
| Official title | Phase I, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Subjects With Advanced Multiple Myeloma |
| Lead sponsor | Facet Biotech, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | HuLuc63 |
| Enrollment | 35 |
| Start date | Dec 1, 2006 |
| Primary completion | Aug 1, 2008 |
| Completion | Jul 1, 2009 |
| First posted | Jan 22, 2007 |
| Last update posted | Sep 23, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: